文献速递帕金森病与运动障碍认知障碍与痴呆

新发帕金森病步态参数的双重多巴胺能与边缘-认知贡献

Dual Dopaminergic and Limbic-Cognitive Contributions to Gait Parameters in De Novo Parkinson Disease.
PubMed 文献 · Neurology · 2026-07-10

该前瞻性研究纳入122例新发帕金森病患者和177名健康对照,通过步态分析、脑MRI、18F-FP-CIT PET及运动认知评估,发现边缘系统灰质体积通过认知中介影响步长/步幅,而纹状体多巴胺转运体可用度直接影响步态节律性,支持步态调节的双通路模型。

要点

  • 边缘系统灰质体积与步长/步幅的关联19%-50%由整体认知中介。
  • 壳核DAT可用度降低与站立时间和双支撑时间变异性增加相关。
  • 尾状核DAT可用度降低与摆动和单支撑时间延长及相位参数改变相关。

核心结论

  • 新发帕金森病步态障碍存在双通路:纹状体多巴胺能去神经支配直接影响步态节律性,边缘系统萎缩通过直接及认知中介途径影响步态。

研究设计与样本

  • 前瞻性研究连续纳入符合英国脑库临床标准的新发帕金森病患者和无局灶神经症状及帕金森综合征的健康对照。
  • 所有参与者接受GAITRite步态分析,患者另接受脑MRI灰质体积测量、18F-FP-CIT PET评估纹状体DAT可用度及运动和认知评估。
  • 采用因果中介分析检验神经影像生物标志物对步态参数的影响是否由认知或运动症状严重程度中介。

主要发现

  • 共纳入122例新发帕金森病患者(平均年龄69.66岁,女性45.90%)和177名健康对照(平均年龄72.07岁,女性51.41%)。
  • 与健康对照相比,帕金森病患者步速更慢、步长/步幅更短、摆动和单支撑时间减少、双支撑时间增加,且多个步态域离散度更大。
  • 边缘系统相关灰质体积与步长/步幅及时间相位组成相关,整体认知中介比例19%-50%(代表性ACMEs:后扣带回1.9559[0.5606-4.2238],海马3.6722[1.0707-8.2118],丘脑2.8794[0.0408-7.2535],杏仁核4.9696[1.8241-10.3405])。
  • 壳核DAT可用度降低与站立时间和双支撑时间变异性增加相关,尾状核DAT可用度降低与摆动和单支撑时间延长及相位参数改变相关。
  • 上述关联未受运动迟缓/强直评分显著中介,直接效应仍显著(ADEs:尾状核-摆动时间-0.0237[-0.0428至-0.0086],壳核-双支撑时间变异性-2.0249[-3.1445至-0.8835])。

临床怎么用

  • 临床评估新发帕金森病步态障碍时,除关注多巴胺能缺陷外,应评估认知功能及边缘系统结构改变。
  • 步态节律性异常可能更多反映纹状体多巴胺能去神经支配,而步长/步幅异常可能与认知中介的边缘系统萎缩相关。

局限性

  • 研究纳入的是未用药的新发帕金森病患者,可能限制结论推广至更广泛的帕金森病谱系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Parkinson disease (PD) is a progressive neurodegenerative disease in which gait impairment is a common and disabling clinical feature. We aimed to characterize the independent and mediated contributions of striatal dopamine transporter (DAT) availability and gray matter (GM) volume to quantitative gait impairment in de novo PD. METHODS: In this prospective study, we consecutively recruited patients with de novo PD fulfilling the UK Brain Bank clinical criteria and healthy controls (HCs) without focal neurologic symptoms and parkinsonism at Wonju Severance Christian Hospital. All participants underwent GAITRite-based gait analysis, and patients further underwent brain MRI for GM volumetry, 18F-FP-CIT PET for striatal DAT availability, and motor and cognitive assessments. After exploratory gait-related correlation analyses, causal mediation analyses tested whether the effects of neuroimaging biomarkers on gait parameters were mediated by cognition or motor symptom severity. RESULTS: A total of 122 patients with de novo PD (mean age, 69.66 years; 45.90% female) and 177 HCs (mean age, 72.07 years; 51.41% female) were enrolled. Compared with HCs, patients with PD showed slower velocity, shorter step/stride lengths, reduced swing and single-support time, increased double-support time, and greater dispersion across multiple gait domains. Limbic-related GM volumes were associated with step/stride lengths and temporal phase composition, and these associations were substantially mediated by global cognition (representative ACMEs [95% CIs] for stride length: posterior cingulate cortex, 1.9559 [0.5606-4.2238]; hippocampus, 3.6722 [1.0707-8.2118]; thalamus, 2.8794 [0.0408-7.2535]; amygdala, 4.9696 [1.8241-10.3405]; proportions mediated, 19%-50%). Lower putaminal DAT availability was associated with greater stance time and double-support time variability, whereas lower caudate DAT availability was associated with longer swing and single-support time and altered phase parameters. These associations were not significantly mediated by bradykinesia/rigidity scores; direct effects remained significant (ADEs [95% CIs]: caudate-swing time, -0.0237 [-0.0428 to -0.0086]; putamen-double-support time variability, -2.0249 [-3.1445 to -0.8835]). DISCUSSION: These findings support a dual-pathway model of gait regulation in patients with de novo PD, where striatal dopaminergic denervation directly affects gait rhythmicity, whereas limbic system atrophy affects gait through direct and cognition-mediated pathways. This medication-naïve cohort may limit generalizability to the broader PD spectrum.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Kim SW, Lee MJ, Kim JW, et al. Dual Dopaminergic and Limbic-Cognitive Contributions to Gait Parameters in De Novo Parkinson Disease. Neurology. 2026. PMID: 42430674. doi:10.1212/WNL.0000000000218223

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。